Morphic Therapeutic Announces Initiation of EMERALD-1 Phase IIa Clinical Trial of MORF-057 in Patients with Ulcerative Colitis

Morphic Therapeutic announced the initiation of MORF-057-201, the EMERALD-1 study, a Phase IIa trial of MORF-057 in patients with moderate to severe ulcerative colitis.